X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA GLENMARK PHARMA SHASUN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 123.9 13.6 908.6% View Chart
P/BV x 8.5 3.8 223.4% View Chart
Dividend Yield % 0.2 0.3 70.1%  

Financials

 SHASUN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
GLENMARK PHARMA
Mar-16
SHASUN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs941,262 7.5%   
Low Rs46672 6.8%   
Sales per share (Unadj.) Rs214.2270.6 79.2%  
Earnings per share (Unadj.) Rs5.324.9 21.4%  
Cash flow per share (Unadj.) Rs15.834.4 46.0%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.2 691.5%  
Book value per share (Unadj.) Rs53.3151.3 35.2%  
Shares outstanding (eoy) m56.62282.16 20.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.6 9.1%   
Avg P/E ratio x13.138.9 33.7%  
P/CF ratio (eoy) x4.428.1 15.7%  
Price / Book Value ratio x1.36.4 20.5%  
Dividend payout %18.78.0 233.1%   
Avg Mkt Cap Rs m3,958272,778 1.5%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m2,16413,782 15.7%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m12,12776,340 15.9%  
Other income Rs m229356 64.4%   
Total revenues Rs m12,35676,696 16.1%   
Gross profit Rs m1,00914,172 7.1%  
Depreciation Rs m5942,691 22.1%   
Interest Rs m4151,789 23.2%   
Profit before tax Rs m23010,048 2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-733,028 -2.4%   
Profit after tax Rs m3027,019 4.3%  
Gross profit margin %8.318.6 44.8%  
Effective tax rate %-31.730.1 -105.0%   
Net profit margin %2.59.2 27.1%  
BALANCE SHEET DATA
Current assets Rs m6,88459,096 11.6%   
Current liabilities Rs m8,45640,018 21.1%   
Net working cap to sales %-13.025.0 -51.9%  
Current ratio x0.81.5 55.1%  
Inventory Days Days6275 82.2%  
Debtors Days Days108119 90.2%  
Net fixed assets Rs m4,97039,075 12.7%   
Share capital Rs m113282 40.1%   
"Free" reserves Rs m2,87530,281 9.5%   
Net worth Rs m3,02042,703 7.1%   
Long term debt Rs m1,81724,873 7.3%   
Total assets Rs m13,347111,026 12.0%  
Interest coverage x1.66.6 23.5%   
Debt to equity ratio x0.60.6 103.3%  
Sales to assets ratio x0.90.7 132.1%   
Return on assets %5.47.9 67.7%  
Return on equity %10.016.4 60.9%  
Return on capital %13.317.5 76.1%  
Exports to sales %46.443.3 107.1%   
Imports to sales %14.27.4 191.7%   
Exports (fob) Rs m5,62233,044 17.0%   
Imports (cif) Rs m1,7285,672 30.5%   
Fx inflow Rs m5,84336,945 15.8%   
Fx outflow Rs m2,17361,066 3.6%   
Net fx Rs m3,669-24,122 -15.2%   
CASH FLOW
From Operations Rs m3983,449 11.5%  
From Investments Rs m-1,635-8,802 18.6%  
From Financial Activity Rs m1,3096,986 18.7%  
Net Cashflow Rs m71934 7.6%  

Share Holding

Indian Promoters % 39.2 48.3 81.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 6.9 52.2%  
FIIs % 17.6 34.4 51.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.5 377.1%  
Shareholders   20,750 56,727 36.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - J.B.CHEMICALS COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS